FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904356201> ?p ?o ?g. }

• W2904356201 endingPage "464" @default.
• W2904356201 startingPage "456" @default.
• W2904356201 abstract "Hunter syndrome (mucopolysaccharidosis II [MPS II]), a deficiency of iduronate-2-sulfatase (IDS), causes an accumulation of glycosaminoglycans, giving rise to multiple systemic and CNS symptoms. The currently available therapies, idursulfase and idursulfase beta, are ineffective against the CNS symptoms because they cannot pass the blood-brain barrier (BBB). A novel IDS fused with anti-human transferrin receptor antibody (JR-141) has been shown to penetrate the BBB and ameliorate learning deficits in model mice. This first-in-human study evaluated the pharmacokinetics, safety, and potential efficacy of JR-141 in 14 patients with MPS II. In a dose-escalation study performed in two patients, JR-141 plasma concentrations were dose dependent and peaked at 3 hr after initiation of each infusion, and no or only mild adverse reactions were exhibited. In a subsequent 4-week evaluation at two dose levels, the plasma concentration profiles were similar between the first and final administration, indicating no drug accumulation. Levels of heparan sulfate (HS) and dermatan sulfate (DS) were suppressed in both plasma and urine and HS levels were significantly decreased in cerebrospinal fluid. Two patients experienced some amelioration of neurocognitive and motor symptoms. These results suggest that the drug successfully penetrates the BBB and could have CNS efficacy. Hunter syndrome (mucopolysaccharidosis II [MPS II]), a deficiency of iduronate-2-sulfatase (IDS), causes an accumulation of glycosaminoglycans, giving rise to multiple systemic and CNS symptoms. The currently available therapies, idursulfase and idursulfase beta, are ineffective against the CNS symptoms because they cannot pass the blood-brain barrier (BBB). A novel IDS fused with anti-human transferrin receptor antibody (JR-141) has been shown to penetrate the BBB and ameliorate learning deficits in model mice. This first-in-human study evaluated the pharmacokinetics, safety, and potential efficacy of JR-141 in 14 patients with MPS II. In a dose-escalation study performed in two patients, JR-141 plasma concentrations were dose dependent and peaked at 3 hr after initiation of each infusion, and no or only mild adverse reactions were exhibited. In a subsequent 4-week evaluation at two dose levels, the plasma concentration profiles were similar between the first and final administration, indicating no drug accumulation. Levels of heparan sulfate (HS) and dermatan sulfate (DS) were suppressed in both plasma and urine and HS levels were significantly decreased in cerebrospinal fluid. Two patients experienced some amelioration of neurocognitive and motor symptoms. These results suggest that the drug successfully penetrates the BBB and could have CNS efficacy." @default.
• W2904356201 created "2018-12-22" @default.
• W2904356201 creator A5010544276 @default.
• W2904356201 creator A5015098092 @default.
• W2904356201 creator A5019881008 @default.
• W2904356201 creator A5023508083 @default.
• W2904356201 creator A5040926154 @default.
• W2904356201 creator A5043488602 @default.
• W2904356201 creator A5054073636 @default.
• W2904356201 creator A5065382621 @default.
• W2904356201 creator A5078779925 @default.
• W2904356201 creator A5081462168 @default.
• W2904356201 date "2019-02-01" @default.
• W2904356201 modified "2023-10-10" @default.
• W2904356201 title "Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial" @default.
• W2904356201 cites W1964975620 @default.
• W2904356201 cites W1967386288 @default.
• W2904356201 cites W1968265417 @default.
• W2904356201 cites W1993027304 @default.
• W2904356201 cites W1993518098 @default.
• W2904356201 cites W1996799982 @default.
• W2904356201 cites W1997831257 @default.
• W2904356201 cites W2012973972 @default.
• W2904356201 cites W2020409398 @default.
• W2904356201 cites W2025061302 @default.
• W2904356201 cites W2027190940 @default.
• W2904356201 cites W2033935474 @default.
• W2904356201 cites W2102067858 @default.
• W2904356201 cites W2106493886 @default.
• W2904356201 cites W2109699895 @default.
• W2904356201 cites W2110569992 @default.
• W2904356201 cites W2112373900 @default.
• W2904356201 cites W2133765656 @default.
• W2904356201 cites W2137541358 @default.
• W2904356201 cites W2138037217 @default.
• W2904356201 cites W2148045371 @default.
• W2904356201 cites W2162676548 @default.
• W2904356201 cites W2584577473 @default.
• W2904356201 cites W2617895008 @default.
• W2904356201 cites W2754733929 @default.
• W2904356201 cites W2765910122 @default.
• W2904356201 cites W2793073482 @default.
• W2904356201 cites W2830135676 @default.
• W2904356201 cites W2884044665 @default.
• W2904356201 doi "https://doi.org/10.1016/j.ymthe.2018.12.005" @default.
• W2904356201 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6391590" @default.
• W2904356201 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30595526" @default.
• W2904356201 hasPublicationYear "2019" @default.
• W2904356201 type Work @default.
• W2904356201 sameAs 2904356201 @default.
• W2904356201 citedByCount "91" @default.
• W2904356201 countsByYear W29043562012019 @default.
• W2904356201 countsByYear W29043562012020 @default.
• W2904356201 countsByYear W29043562012021 @default.
• W2904356201 countsByYear W29043562012022 @default.
• W2904356201 countsByYear W29043562012023 @default.
• W2904356201 crossrefType "journal-article" @default.
• W2904356201 hasAuthorship W2904356201A5010544276 @default.
• W2904356201 hasAuthorship W2904356201A5015098092 @default.
• W2904356201 hasAuthorship W2904356201A5019881008 @default.
• W2904356201 hasAuthorship W2904356201A5023508083 @default.
• W2904356201 hasAuthorship W2904356201A5040926154 @default.
• W2904356201 hasAuthorship W2904356201A5043488602 @default.
• W2904356201 hasAuthorship W2904356201A5054073636 @default.
• W2904356201 hasAuthorship W2904356201A5065382621 @default.
• W2904356201 hasAuthorship W2904356201A5078779925 @default.
• W2904356201 hasAuthorship W2904356201A5081462168 @default.
• W2904356201 hasBestOaLocation W29043562011 @default.
• W2904356201 hasConcept C112705442 @default.
• W2904356201 hasConcept C126322002 @default.
• W2904356201 hasConcept C197934379 @default.
• W2904356201 hasConcept C22814914 @default.
• W2904356201 hasConcept C2776225084 @default.
• W2904356201 hasConcept C2777636572 @default.
• W2904356201 hasConcept C2779134260 @default.
• W2904356201 hasConcept C2779416428 @default.
• W2904356201 hasConcept C2779969927 @default.
• W2904356201 hasConcept C2910638406 @default.
• W2904356201 hasConcept C32264632 @default.
• W2904356201 hasConcept C71924100 @default.
• W2904356201 hasConcept C98274493 @default.
• W2904356201 hasConceptScore W2904356201C112705442 @default.
• W2904356201 hasConceptScore W2904356201C126322002 @default.
• W2904356201 hasConceptScore W2904356201C197934379 @default.
• W2904356201 hasConceptScore W2904356201C22814914 @default.
• W2904356201 hasConceptScore W2904356201C2776225084 @default.
• W2904356201 hasConceptScore W2904356201C2777636572 @default.
• W2904356201 hasConceptScore W2904356201C2779134260 @default.
• W2904356201 hasConceptScore W2904356201C2779416428 @default.
• W2904356201 hasConceptScore W2904356201C2779969927 @default.
• W2904356201 hasConceptScore W2904356201C2910638406 @default.
• W2904356201 hasConceptScore W2904356201C32264632 @default.
• W2904356201 hasConceptScore W2904356201C71924100 @default.
• W2904356201 hasConceptScore W2904356201C98274493 @default.
• W2904356201 hasFunder F4320307781 @default.
• W2904356201 hasFunder F4320309052 @default.
• W2904356201 hasFunder F4320309705 @default.
• W2904356201 hasFunder F4320310557 @default.

• next